Shandong Henglu Biotechnology Co., Ltd. was founded in March 2018, headquartered in Jinan City, Shandong Province. It is a leading synthetic biology enterprise, focusing on synthetic biology industry technology research and development and transformation of scientific and technological achievements, with the "biological" preparation of breast milk oligosaccharides (HMOs) series of products as the key direction of scientific and technological achievements, and is committed to the popularization of the independently developed and produced high-value-added raw materials in the field of infant formula, functional foods, special foods, cosmetics, pharmaceuticals and popularization of the application of the product.
Prof. Fang, the founder of Henglu Biology, "Taishan Scholar" and "Taishan Industry Leading Talent", Pro. Fang led the research and development team to innovate the "enzyme/yeast dual method" technology path independently. This process uses carbohydrates as substrates, and applies a new technology pioneered domestically and internationally to synthesize six types of breast milk oligosaccharides successfully(LNB, LNT, LNnT, LNT II, 2'-FL, LNFP II), achieving the mass production of multiple HMOs. Henglu is the only one in China to realize the mass production of HMOs has developed a green, energy-saving, high-efficiency, and completely different from Europe and the United States. The technical path has broken through the “bottleneck” technical problem in this field in China.
At this stage, the raw materials being researched by Henglu Biology not only cover breast milk oligosaccharides series of products, but also continue to make breakthroughs in the commercialization of Rhodiola rosea crude extracts, new substances Rhodiola rosea glycoside II, tyrosol, hydroxytyrosol and other polyphenolic active molecules, and continue to promote the globalization of high-value patents layout, build high technical barriers, and fill the domestic gaps. Relying on strong R&D strength, Henglu has created brands such as Yifanglan cosmetics series and Aishe pet food series.
At present, Henglu Biology has set up a bio-intelligent synthetic biology R&D platform, using software engineering technology to implement global rational design for industrial microorganisms, simulating the process of high-throughput screening of strains in synthetic biology with AI technology, and comprehensively accelerating the process of new product R&D to mass production. The R&D platform of "Synthetic Biology + Artificial Intelligence" has realized the efficient integration of the biotechnology research team and the information technology development team. Henglu Biology has built a high-end R&D team with a multidisciplinary crossover and with the core of returnees and PhDs from famous universities in China.
Up to now, Henglu Biology has a R&D platform of "New Research and Development Institution in Shandong Province" and "Key Laboratory of Synthetic Biology in Weihai City", and has been reported by many domestic media as "a company that makes biochips"; in 2021, it will be awarded by the Ministry of Industry and Information Technology as one of the 52 Morning Star Enterprises with the most innovative capabilities and the ability to drive industrial development in China; in 2022, Henglu has won the Award of Excellence of the Ministry of Science and Technology for its National Disruptive Technological Innovation Competition; and Henglu has been selected to be in the "Top 100 Unicorns of the Future" TOP100 list in the "2022 China New Economy Top 100 Unicorns and Benchmarking Enterprise Research Report".